Thermo Fisher Enables Scalable Gene Therapy Workflows
New Gibco AAV-MAX Helper Free AAV Production System Helps Reduce Production Costs
Responding to the need to make adeno-associated virus (AAV) production more efficient and scalable, Thermo Fisher Scientific has launched the free Gibco AAV-MAX Helper AAV production system, a complete and optimized solution that simplifies the workflow of vectors. AAV.
The all-in-one AAV-MAX system increases productivity and profitability by delivering high viral titers using Viral Production Cells 2.0, a novel 293F-derived mammalian cell line documented by cloning.
AAV is crucial in the field of gene therapy; more than 1,300 unique gene therapy products are currently in development, and almost half depend on AAV. The ability to increase production is essential to reduce costs and accelerate the process from research to commercialization.
The AAV-MAX system was developed to adapt from shake flasks to bioreactors. Coupled with the active development of regulatory compliant reagents **, the system is designed to streamline the transition from research to commercial manufacturing. On average, the system allows viral vector researchers and developers to save 25% on plasmid DNA usage and 50% on production costs compared to polyethyleneimine (PEI) -based mammalian production systems. . When used in conjunction with Thermo Fisher’s expanded portfolio of gene therapy products,